Stephen M. Sykes

The p53 family and programmed cell death.

Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53.

Proplatelet generation in the mouse requires PKCε-dependent RhoA inhibition.

Modeling human hematopoietic stem cell biology in the mouse.

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Inhibiting stromal cell heparan sulfate synthesis improves stem cell mobilization and enables engraftment without cytotoxic conditioning.

mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.

Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia.

The identity crisis of Hif-1α in HSC biology.

A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.

JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity.

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.

NCAM1 supports therapy resistance and LSC function in AML.